Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Roth

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Transplantation|January 22, 2014
Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: a single-center observational studyJeffrey J Gaynor, Gaetano Ciancio, Giselle Guerra, et al.
Diabetologia|November 2, 2014
Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplantJeffrey J Gaynor, Gaetano Ciancio, Giselle Guerra, et al.
F1000Research|March 17, 2017
Impact of antiretroviral therapy on clinical outcomes in HIV <sup>+</sup> kidney transplant recipients: Review of 58 casesRossana Rosa, Jose F Suarez, Marco A Lorio, et al.
Clinical Transplantation|January 13, 2015
Multivariable risk of developing new onset diabetes after transplant-results from a single-center study of 481 adult, primary kidney transplant recipientsJeffrey J Gaynor, Gaetano Ciancio, Giselle Guerra, et al.
Clinical Transplantation|March 14, 2019
Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experienceJose F Camargo, Shweta Anjan, Nafeesa Chin-Beckford, et al.
Seminars in Nuclear Medicine|April 4, 2009
A renal protocol for all ages and all indications: mercapto-acetyl-triglycine (MAG3) with simultaneous injection of furosemide (MAG3-F0): a 17-year experienceGeorge N Sfakianakis, Efrosyni Sfakianaki, Mike Georgiou, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Journal of Hepatology|June 23, 2015
Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal diseaseKalyan Ram Bhamidimarri, Bhamidimarri Kalyan Ram, Frank Czul, et al.
Transplantation|December 25, 2002
Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantationSandy Feng, Joseph F Buell, Wida S Cherikh, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2015
Genome editing technologies: defining a path to clinicJacqueline Corrigan-Curay, Marina O'Reilly, Donald B Kohn, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Transplantation|January 22, 2014
Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: a single-center observational studyJeffrey J Gaynor, Gaetano Ciancio, Giselle Guerra, et al.
Diabetologia|November 2, 2014
Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplantJeffrey J Gaynor, Gaetano Ciancio, Giselle Guerra, et al.
F1000Research|March 17, 2017
Impact of antiretroviral therapy on clinical outcomes in HIV <sup>+</sup> kidney transplant recipients: Review of 58 casesRossana Rosa, Jose F Suarez, Marco A Lorio, et al.
Clinical Transplantation|January 13, 2015
Multivariable risk of developing new onset diabetes after transplant-results from a single-center study of 481 adult, primary kidney transplant recipientsJeffrey J Gaynor, Gaetano Ciancio, Giselle Guerra, et al.
Clinical Transplantation|March 14, 2019
Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experienceJose F Camargo, Shweta Anjan, Nafeesa Chin-Beckford, et al.
Seminars in Nuclear Medicine|April 4, 2009
A renal protocol for all ages and all indications: mercapto-acetyl-triglycine (MAG3) with simultaneous injection of furosemide (MAG3-F0): a 17-year experienceGeorge N Sfakianakis, Efrosyni Sfakianaki, Mike Georgiou, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Journal of Hepatology|June 23, 2015
Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal diseaseKalyan Ram Bhamidimarri, Bhamidimarri Kalyan Ram, Frank Czul, et al.
Transplantation|December 25, 2002
Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantationSandy Feng, Joseph F Buell, Wida S Cherikh, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2015
Genome editing technologies: defining a path to clinicJacqueline Corrigan-Curay, Marina O'Reilly, Donald B Kohn, et al.
Pageof 16